Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
January 03 2024 - 6:00AM
Business Wire
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, NSEIFSC: DRREDDY, along with its subsidiaries together
referred to as "Dr. Reddy's"), today announced that it has acquired
MenoLabs® business, a leading women’s health and dietary supplement
branded portfolio from Amyris, Inc. (“Amyris”) in Amyris’ Chapter
11 sales process.
Dr. Reddy’s acquired the entire MenoLabs supplements portfolio
which includes seven branded products designed to provide health
support and address symptoms of perimenopause and menopause. Brands
include MenoFit™ and MenoGlow™ probiotics, Happy Fiber™ and Well
Rested™ dietary supplements, Athena’s Shield™ menopause support
supplement, and Goodness Glow™ and Keep Glowing Gorgeous™
supplements for healthy aging support. The deal also includes the
MenoLife® health tracker app which supports the product line and
provides community, education, and information to consumers
regarding menopause. MenoLabs portfolio of products is sold in the
United States, primarily through the brand’s own
[https://menolabs.com] and other e-commerce marketplaces including
Amazon and Walmart.
“The MenoLabs acquisition will serve as a catalyst to accelerate
growth in this space and build upon our aspiration to lead in the
fast-growing women’s nutritional and wellness markets,” says Marc
Kikuchi, Chief Executive Officer for Dr. Reddy’s in North America.
“The acquisition complements Dr. Reddy’s U.S. self-care and
wellness business portfolio of brands and addresses unmet needs of
consumers for science-based, research-driven products that provide
relief from the symptoms of menopause. For these and many other
reasons, I believe we are well-positioned to successfully integrate
and grow the business.”
RDY-1123-OTC
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global
pharmaceutical company headquartered in Hyderabad, India.
Established in 1984, we are committed to providing access to
affordable and innovative medicines. Driven by our purpose of ‘Good
Health Can’t Wait’, we offer a portfolio of products and services
including APIs, generics, branded generics, biosimilars and OTC.
Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and
dermatology. Our major markets include – USA, India, Russia &
CIS countries, China, Brazil and Europe. As a company with a
history of deep science that has led to several industry firsts, we
continue to plan ahead and invest in businesses of the future. As
an early adopter of sustainability and ESG actions, we released our
first Sustainability Report in 2004. Our current ESG goals aim to
set the bar high in environmental stewardship; access and
affordability for patients; diversity; and governance. For more
information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults, currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the susceptibility
of our industry and the markets addressed by our, and our
customers’, products and services to economic downturns as a result
of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (or COVID-19), and (vii) other risks
and uncertainties identified in our public filings with the
Securities and Exchange Commission, including those listed under
the "Risk Factors" and "Forward-Looking Statements" sections of our
Annual Report on Form 20-F for the year ended March 31, 2023. The
company assumes no obligation to update any information contained
herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103256319/en/
INVESTOR RELATIONS RICHA PERIWAL richaperiwal@drreddys.com
MEDIA RELATIONS USHA IYER USHAIYER@DRREDDYS.COM
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2024 to May 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From May 2023 to May 2024